Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.
about
Novel agents and biomarkers for acute lymphoid leukemiaDual effect of oxidative stress on leukemia cancer induction and treatmentFludarabine, idarubicin, and cytarabine regimen together with TKI followed by haploidentical hematopoietic stem cell transplantation, a success for relapsed Ph+ acute lymphoblastic leukemiaSubdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy.Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.Role of allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia.FLT3/ITD AML and the law of unintended consequences.Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemiaFavorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest ChinaImpact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell TransplantationImatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup studyMonoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemiaOutcomes of Adults with Acute Lymphoblastic Leukemia After Autologous Hematopoietic Stem Cell Transplantation and the Significance of Pretransplantation Minimal Residual Disease: Analysis from a Single Center of China.Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohortsUKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Results from a Single Center, 1993-2011.Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options.Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.Treatment of acute lymphoblastic leukemia in adolescents and young adults.Philadelphia-positive acute lymphoblastic leukemia: current treatment optionsOptimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools.Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates.Emerging drugs for acute lymphocytic leukemia.Insights on practice variations in the management of lymphoma and leukemia.Current and future management of Ph/BCR-ABL positive ALL.Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus.The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia.The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.
P2860
Q26829775-C7905DCB-4E1E-42DB-BC6C-1BC2626E2B50Q26866544-C055D8A8-3111-47A6-B18C-FE9A30E6B049Q30276948-B5227BB9-A2C6-4003-88B7-0A3220CF77FFQ33395138-BB0DF560-5C40-49F9-B7BF-066ECC5B9B4BQ33558183-E075EBF2-A5A7-4678-A626-37BCC4DB8434Q33762835-4BE3D78A-B13F-43C8-9240-281AAF5BA78FQ33822032-619679A1-7DF7-41DA-9526-577C842A0CD3Q34532041-35FABC66-B31D-4A1B-8FBD-32E57CA0BC5AQ35127958-B21E8F24-3D9B-48E6-B00A-E25D07AFE987Q35146312-8B4B0ADE-7411-4FAA-B128-274E35AB23B7Q35199893-0AFE0C6F-2FD6-4F54-9EC9-10A57E245507Q35571035-3B3AC694-0379-4D4F-9E44-500F0A2E5F74Q35669875-5BF26DBF-BE96-4141-BB14-39C348487BEEQ35888941-CE8B7C21-38E2-44F9-9ADB-23B5223969D8Q36108349-F84071B3-AB5B-4C78-B475-6581ADB14065Q36201257-4CC8106A-644D-4936-94B6-838A0386D4C0Q36339717-1144354F-3899-440A-981E-FA9ADAA2DEF4Q36477219-AF0FBF4C-19B7-45D5-9759-A2B339FD58CFQ36591877-10BB6649-9058-4DC6-8F33-E0904F099EE8Q36751420-53F45BA8-A099-4141-9085-12770427250EQ36811503-F5957AEA-0243-4E5D-B5E9-E979E97DC10EQ37273171-7FFFE51E-62FB-4324-8A8D-01A4AA9E1C66Q37564762-14B89ECD-4297-423A-892E-D645F3EE6B25Q37632798-2735E142-7E29-44EC-ABC2-6EBE43251315Q37682126-E515645F-05B4-41AF-B5C8-8F316EE76226Q37810967-0AD877C4-B1DF-4A35-B564-A1D498CFA6BFQ37887580-7C30049B-5E65-4A9C-9CED-689A32DBE367Q37899785-D7E1D08F-0F83-4FC8-A092-50259B76E6C8Q38016343-555CB7F8-9937-451F-B357-EEE4DD28D9C3Q38023947-3629A58D-EA5E-4DD8-813A-F9E0715FE120Q38087930-2A506391-6790-4321-B59E-7FADF2888E3BQ38095113-6932624F-043E-4594-9C2D-A9F453152522Q38172586-E4660E49-F8A0-415A-9B23-6540601FFCACQ38177354-FAF76FA2-3FEC-474D-B062-E755D056DA4FQ38194585-38020D8E-DD31-47C8-B6DE-264CC984F3AFQ38207017-D4600B12-FD74-4BDC-A3BE-B58CDC318BA7Q38375425-2B0D8A97-ECCF-4981-8DD4-AE6676AEED63Q38423781-4BFF0BC5-1356-4CE8-AFAF-154DA469DAACQ38428357-80C43223-2919-462A-9570-27A7D01B6F24Q38674733-A52FDEEE-9EB5-4F1F-A648-09F3E06C1D68
P2860
Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Chemotherapy-phased imatinib p ...... Leukemia Group protocol 09/00.
@en
Chemotherapy-phased imatinib p ...... Leukemia Group protocol 09/00.
@nl
type
label
Chemotherapy-phased imatinib p ...... Leukemia Group protocol 09/00.
@en
Chemotherapy-phased imatinib p ...... Leukemia Group protocol 09/00.
@nl
prefLabel
Chemotherapy-phased imatinib p ...... Leukemia Group protocol 09/00.
@en
Chemotherapy-phased imatinib p ...... Leukemia Group protocol 09/00.
@nl
P2093
P921
P356
P1476
Chemotherapy-phased imatinib p ...... Leukemia Group protocol 09/00
@en
P2093
Alessandro Levis
Alessandro Rambaldi
Carlo Borghero
Claudio Romani
Elena Oldani
Elisabetta Terruzzi
Enrico M Pogliani
Erika Borlenghi
Eros Di Bona
Fabio Ciceri
P304
P356
10.1200/JCO.2010.28.1287
P407
P577
2010-07-06T00:00:00Z